Novartis (NYSE: NVS) failed to convince a U.S. appeals court on Wednesday to halt MSN Pharmaceuticals’ proposed generic of Novartis’ […]
US Appeals Court Rules Against Novartis in Heart Drug Patent Case Read More »
FRANKFURT – Novartis (NYSE: NVS) raised its medium-term sales guidance on Thursday to 6% annual growth through 2028, driven by
Novartis Raises Sales Guidance Until 2028 Read More »
ZURICH – Novartis (NYSE: NVS) expects to increase its annual sales by at least 5% per year in the coming
Novartis CEO ‘Very Confident’ on Sales Target, Doesn’t Fear Patent Cliff – Newspaper Read More »
FRANKFURT – Novartis, the Swiss drugmaker, raised its 2024 earnings guidance on Tuesday for the third time buoyed by wider
Novartis Lifts 2024 Earnings Outlook Again on Strong Cosentyx Demand Read More »
Novartis (NYSE: NVS), the Swiss pharmaceutical giant, will pay Monte Rosa Therapeutics (NASDAQ: GLUE) $150 million upfront payment for a
Novartis to Pay Monte Rosa $150 Million Upfront to Develop New Class of Drugs Read More »
BERLIN – Switzerland’s COMCO competition commission terminated an investigation against Novartis (NYSE: NVS) into possibly using blocking patents, without consequences,
COMCO Ends Probe into Novartis Patent Practices, Finds No Wrongdoing Read More »
On Saturday, Novartis (NYSE: NVS), a Swiss drugmaker, said it had received a binding offer from Germany’s Siemens Healthineers to
On Monday, Novartis (NYSE: NVS) and Viatris (NASDAQ: VTRS) were hit with a federal lawsuit in Maryland by the family
FRANKFURT – Swiss drugmaker Novartis (NYSE: NVS) raised its 2024 earnings guidance for the second time on Thursday, driven by
Novartis (NYSE: NVS) Upgrades Profit Outlook for Second Time Read More »
Copyright © 2024 abbonews.com
